Tag label 1

medwireNews: Patients with primary biliary cholangitis (PBC) who continue treatment with seladelpar beyond 12 months experience… ongoing improvements in pruritus and biochemical markers of cholestasis, with few adverse events, demonstrate two analyses of the ASSURE trial.